Legacy Financial Advisors Inc. Takes $295,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Legacy Financial Advisors Inc. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 3,198 shares of the biopharmaceutical company's stock, valued at approximately $295,000.

A number of other institutional investors also recently bought and sold shares of GILD. HHM Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences during the fourth quarter worth $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter valued at about $29,000. Crews Bank & Trust bought a new position in Gilead Sciences during the fourth quarter worth $31,000. Finally, Stephens Consulting LLC lifted its position in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 260 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of GILD stock traded up $0.17 on Wednesday, hitting $105.85. 1,628,791 shares of the stock traded hands, compared to its average volume of 7,473,408. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company's fifty day moving average is $108.63 and its 200 day moving average is $97.11. The company has a market capitalization of $131.80 billion, a PE ratio of 286.08, a PEG ratio of 0.71 and a beta of 0.32.

Remove Ads

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a $0.79 dividend. The ex-dividend date was Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.99%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is currently 854.05%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the company's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 300,285 shares of company stock worth $30,274,875. Insiders own 0.16% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, Oppenheimer boosted their target price on Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 4th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.